Similar to STAT3 pharmacological treatment, the genetically-based STAT3 silencing in myeloid compartment controlled the weight loss, limiting CRS-associated cachexia (Supplementary information, Fig. S6A). This evidence concerns the gene STAT3 and congenital rubella syndrome.